# Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer

> **NCT00267020** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 130 (actual)

## Conditions studied

- Pancreatic Neoplasm

## Interventions

- **DRUG:** enzastaurin
- **DRUG:** gemcitabine

## Key facts

- **NCT ID:** NCT00267020
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2020-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00267020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00267020, "Phase 2 Study of Gemcitabine or Gemcitabine + Enzastaurin in Participants With Advanced or Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00267020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*